Bactericidal/permeability-increasing protein (BPI) and BPI homologs at mucosal sites.

Trends Immunol

Department of Gynecology, Obstetrics and Medical Genetics, Central University Hospital of Vaud (CHUV), 1011 Lausanne, Switzerland.

Published: November 2008

At mucosal surfaces, we must co-exist with a high density of diverse microorganisms; therefore, protection against these occurs on multiple levels. Leukocyte- and epithelial derived-antimicrobial peptides and proteins (AMPs) comprise an essential component of immune defense. These molecules possess antibacterial, antifungal and signalling properties and probably contribute to defence and maintenance of homeostasis between the host and commensal microorganisms. Among these AMPs is bactericidal/permeability-increasing protein (BPI), an antimicrobial protein with potent endotoxin-neutralising activity, and several homologs. This review explores the roles of BPI and and its homologs at the mucosal interface. Congeners of BPI are under biopharmaceutical development as novel anti-infective agents, highlighting the potential therapeutic relevance of this protein family.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.it.2008.07.012DOI Listing

Publication Analysis

Top Keywords

bactericidal/permeability-increasing protein
8
protein bpi
8
bpi homologs
8
homologs mucosal
8
bpi
5
bpi bpi
4
mucosal sites
4
sites mucosal
4
mucosal surfaces
4
surfaces co-exist
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!